SBIR-STTR Award

Lab-On-A-Patch for Neonates to Monitor Real-Time Glucose and Reduce Needle Pain
Award last edited on: 11/14/2023

Sponsored Program
STTR
Awarding Agency
NIH : NICHD
Total Award Amount
$224,922
Award Phase
1
Solicitation Topic Code
865
Principal Investigator
Zhenyu Li

Company Information

Zansors LLC

1616 Anderson Road
McLean, VA 22102
   (703) 375-9267
   info@zansors.com
   www.zansors.com

Research Institution

George Washington University

Phase I

Contract Number: 1R41HD088142-01
Start Date: 4/1/2016    Completed: 3/31/2017
Phase I year
2016
Phase I Amount
$224,922
This STTR grant is aimed to reduce pain from repeated needle pricks by improving the monitoring of glucose homeostasis (GH) in neonates by developing a real-time glucose monitoring device. The innovation utilizes a micro-needle based lab-on-a-patch platform invented by STTR partner, George Washington University (GWU). GH is usually monitored by blood test via a heel stick, or blood is sent to the lab for confirmation but variation from actual levels may be as much as 10-20 mg/dL. Infants at risk for GH may require glucose testing every three hours or 8 times/day necessitating a needle prick on the heel to obtain a blood sample and then using a bedside reagent test-strip glucose analyzers. The lack of real-time glucose monitors in neonates is a major unmet need for reducing sample volume collection and needle pricks. A bendable, stretchable microfluidic patch for real-time monitoring of glucose using interstitial fluids (or blood) in NICU infants will be th first product for reducing pain and the frequency of needle pricks to once every 24 hours. This biosensor will securely communicate with a smartphone app via Zansors mobile health IT cloud system. Proof-of-principle data by GWU was shown in Nature's Scientific Reports Jan. 2013 reporting a miniaturized lab-on-a-patch technology integrating semiconductor/CMOS sensors and electronics with microfluidics on a flexible substrate via liquid metal interconnects. Zansors' possesses an innovative telemedicine system with encryption and HIPAA compliance that can be integrated to this proposed device. Phase I Hypothesis: A bendable, stretchable sensor platform that integrates a hybrid of CMOS electrochemical sensors/electronics chip, microfluidic channels, and stretchable electrical interconnects may use less interstitial fluid sample and less needle pricks, and offer a real-time sensor that monitors GH and continuously for long terms (24 hours) unobtrusively and then send the secure wireless data to a HIPAA-compliant telemedicine mobile health cloud system. Specific Aim 1: Develop a wearable lab-on-a-patch with micro-needle. Design electrochemical glucose sensors and CMOS electronics in COTS technology; Finish the PDMS microfluidic device design and fabrication with soft lithography. Specific Aim 2: Adapt and calibrate the algorithm to compute GH from fluid data in real-time, and develop a mobile app to collect, process, analyze and store data from the device and communicate with a telemedicine and digital health cloud system. Specific Aim 3: Using glucose solutions, demonstrate a proof-of-principle packaged bendable, stretchable CMOS/Microfluidic system for glucose monitoring. The neonatal glucose monitor market is a subset of the larger continuous glucose monitoring (CGM) market. CGM is set to grow to $568 million by 2020.

Public Health Relevance Statement:


Public Health Relevance:
In this Phase I STTR grant, Zansors in collaboration with George Washington University will improve the monitoring of blood sugar of infants in the neonatal intensive care unit (NICU) by developing a real-time glucose monitoring device, which would be accurate and use a very small sample volume. Most importantly, the infant experiences reduced pain and less needle pricks because the bendable and stretchable lab-on-a- chip technology can be placed on the infant's heel once for 24 hours instead of the current practice of repeated needle pricks every 3 hours. The sensor will be able to transmit wireless data to a health provider's secure mobile phone and also to a mobile cloud system with HIPAA privacy

Project Terms:
Algorithms; Anemia; Area; Award; base; Biosensor; Blood; Blood Glucose; blood glucose regulation; Blood specimen; Blood Tests; Blood Transfusion; Car Phone; Cellular Phone; Clinical; Collaborations; Collection; commercialization; Consumption; cost; Data; design; Detection; Device Designs; Devices; digital; Electrolytes; Electronics; encryption; evidence base; experience; flexibility; Frequencies (time pattern); Glucose; glucose monitor; glucose sensor; Goals; Grant; Health; Health Insurance Portability and Accountability Act; Health Personnel; Heel; Hour; Hybrids; Hypoglycemia; improved; Infant; innovation; Intercellular Fluid; Laboratories; Legal patent; Licensing; Liquid substance; lithography; Marketing; Metals; mHealth; micro-total analysis system; Microfluidic Microchips; Microfluidics; miniaturize; mobile application; Monitor; monitoring device; Nature; Needles; Neonatal; Neonatal Intensive Care Units; neonatal patient; neonate; Nurseries; Pain; pediatric patients; Phase; premature; Premature Infant; Privacy; Process; public health relevance; rapid diagnosis; reagent testing; Reporting; Research; Risk; Safety; Sampling; Secure; Semiconductors; sensor; Small Business Innovation Research Grant; Small Business Technology Transfer Research; Solutions; Stimulus; subcutaneous; System; technological innovation; Technology; Telemedicine; Testing; Time; Transfusion; type I diabetic; Universities; Variant; Washington; Wireless Technology; Withdrawal; Work

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----